Citigroup
RVMD icon

Citigroup’s Revolution Medicines RVMD Stock Holding History

Citigroup’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,000
Closed -$1.1M – 6288
2025
Q2 		$1.1M Hold
30,000
– – ﹤0.01% 3123
2025
Q1 		$1.06M Buy
+30,000
New +$1.22M ﹤0.01% 3220
2024
Q3 		– Sell
-62,600
Closed -$2.43M – 5785
2024
Q2 		$2.43M Buy
62,600
+41,600
+198% +$1.55M ﹤0.01% 2186
2024
Q1 		$677K Sell
21,000
-68,900
-77% -$2.04M ﹤0.01% 3336
2023
Q4 		$2.58M Buy
+89,900
New +$2.16M ﹤0.01% 2031

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citigroup's RVMD Position: Q1 2026 in Review

Citigroup increased its Revolution Medicines (RVMD) stake by 96% in Q1 2026, buying an estimated $4.45M and bringing the position to 89,742 shares worth $8.73M. The position accounts for ﹤0.01% of the portfolio, ranked #1566.

Citigroup first reported a position in RVMD in Q1 2020 and has held it in 25 quarters since. The position peaked at $21.5M in Q1 2025. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Citigroup held 89,742 shares of Revolution Medicines worth $8.73M as of Q1 2026.
  • Citigroup bought 44,040 Revolution Medicines shares in Q1 2026, an estimated $4.45M.
  • Revolution Medicines made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #1566 holding.
  • Citigroup first reported a position in Revolution Medicines in Q1 2020 and has held it in 25 quarters since.
  • Citigroup's Revolution Medicines position peaked at $21.5M in Q1 2025.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.